Unaudited Interim Results to 30 June 2026

Probiotix Health PLC

06 August 2026

6 August 2026

ProBiotix Health plc

("ProBiotix" or the "Company")

Unaudited Interim Results to 30 June 2026

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its unaudited results for the six months to 30 June 2026.

Key Financial Highlights

·    Gross revenue +53% to £2.06m (H1 2025: £1.34m)

·    Gross profit +66% to £1.245m (H1 2025: £748,000)

·    EBITDA profit £151,000* (H1 2025: £112,000 loss)

·    Strong cash balance of £1.244m (H1 2025: £1.3m)

*Excluding share-based payments

Operational Highlights

·    Five new partnerships established

·    Significant growth of existing customer base

·    Strong growth in China through Kemin partnership

·    Repositioned US strategy for stronger market penetration in 2027

·    Recruitment for clinical study to investigate potential impact of LP_LDL® in prediabetes and diabetes

Steen Andersen, CEO of ProBiotix commented: "We are pleased with the performance of the business in the first half of the financial year, and the progress we are making. The active customer base has grown by more than 15% during this period, which reflects the growing demand for effective science-backed preventive cardiometabolic supplement products.

We expect further growth in H2 from APAC and the EMEA regions and going into 2027 through the repositioning of a deeper US offering, expanding sales to include third party distribution and a broadened product positioning to offer LP_LDL® beyond cholesterol health."

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com/
	investors@probiotixhealth.com
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations
AlbR Capital Limited Aquis Corporate Adviser and Broker	Tel: 020 7469 0930
David Coffman Dan Harris

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Notes to Editors:

ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

Chief Executive Officer's overview

The momentum in the business has continued in the first half of 2026, with record revenue growth and a pleasing increase in our gross margin. Moreover, our stated strategy to increase market awareness and boost market penetration, has led to a significant expansion of the customer base.

The Company has continued to expand its global footprint, with the APAC region again proving a particularly strong market. Our partnership with Kemin continues to develop, leading to increasing demand in China.

Revenue for the first six months of 2026 reached a record £2.06m, a 53% increase compared with the same period in 2025. As a result of this increased sales traction, the Group has achieved a swing to an EBITDA profit (excluding share-based payments) for the period of £151,000 (2025: £112,000 loss).

The Board and Management are pleased with the performance achieved in the first half of the year, as it provides further evidence of the success of our strategy.

Strategic Outlook

As a life sciences company with a strategic focus on probiotics and the human microbiome, there remains a significant market opportunity to continue our expansion. ProBiotix operates in the dietary supplement prevention segment, a market which is being driven by the consumer trend of healthy ageing, cardiometabolic health and probiotics.

The strategy continues to target partnerships with scientifically driven dietary supplement suppliers, consumer health and Over the Counter (OTC) companies globally. We continue to provide private label as well as turnkey probiotic dietary supplements to target preventative cardiometabolic health and healthy ageing. The patented LP_LDL® continues to be our flagship probiotic strain, developed specifically to support cardiometabolic health.

Results

The Group has delivered a solid trading result during the period, with revenue increasing 53% to £2.06m (2025: £1.34m). Gross profit rose to £1.245m (2025: £748,000), which equated to an increased gross margin of 60.4% (2025: 55%).

Importantly, the Group has achieved a swing to an EBITDA profit (excluding share-based payments) for the period of £151,000 (2025: £112,000 loss). This improvement has been achieved by increased sales volumes, as well as continued operational efficiencies.

The Group ended the period with a cash and cash equivalents of £1.244m, compared to £1.3m at the prior period end. The movement in the bank balance arises from a higher net trade debtor position relative to trade creditors at the current period end compared with the prior period. This is sufficient to deliver our expansion ambitions and leaves the Group fully funded as a result.

Outlook

The active customer base has grown by more than 15% during this period which reflects the growing demand for effective science-backed preventive cardiometabolic supplement products.

We expect further growth in H2 from APAC and the EMEA regions and going into 2027 through the repositioning of a deeper US offering expanding sales to include third party distribution, and a broadened product positioning to offer LP_LDL® beyond cholesterol health.

The Board and wider management team remain fully committed to delivering the growth strategy we have articulated. We would like to thank all our shareholders and wider stakeholders for their support, and view the future with confidence.

Consolidated Statement of Comprehensive Income

For the 6 months to 30 June 2026

			6 months to 30 June 2026 Unaudited	6 months to 30 June 2025 Unaudited	Year ended 31 December 2025 Audited
Continuing operations			£'000	£'000	£'000
Revenue	3		2,059	1,344	2,732
Cost of sales			(814)	(596)	(1,250)
			───────	───────	───────
Gross Profit			1,245	748	1,482
Share based payments			(46)	(16)	(753)
Depreciation and amortisation			(26)	(25)	(54)
Other administrative costs			(1,094)	(860)	(1,910)
			───────	───────	───────
Total administrative expenses			(1,166)	(901)	(2,717)
			───────	───────	───────
Operating profit/(loss)			79	(153)	(1,235)
Finance income / (costs)			-	-	-
			───────	───────	───────
Profit/(Loss) before Income tax			79	(153)	(1,235)
Income tax			7	3	2
			───────	───────	───────
Profit/(Loss) for the period			86	(150)	(1,233)
Other Comprehensive Income			-	-	-
			───────	───────	───────
Total comprehensive income for the period			86	(150)	(1,233)
			═══════	═══════	═══════
Total comprehensive income attributable to the owners of the Group			86	(150)	(1,233)
			═══════	═══════	═══════
			86	(150)	(1,233)
Earnings/(loss)  per share
Basic & Diluted - pence	4		0.05p	(0.09)p	(0.78)p
			═══════	═══════	═══════

Consolidated Statement of Financial Position

As at 30 June 2026

	Notes	As at 30 June  2026 Unaudited	As at 30 June  2025 Unaudited	As at 31 December  2025 Audited
ASSETS		£'000	£'000	£'000
Non-current assets
Intangibles		161	211	186
Property plant and equipment		6	7	5
		───────	───────	───────
		167	218	191
		───────	───────	───────
CURRENT ASSETS
Inventories		-	17	-
Trade and other receivables		560	846	351
Cash and cash equivalents		1,244	1,299	1,266
		───────	───────	───────
		1,804	2,162	1,617
		───────	───────	───────
TOTAL ASSETS		1,971	2,380	1,808
		═══════	═══════	═══════
EQUITY
Shareholders' Equity
Called up share capital	5	79	79	79
Group reorganisation reserve		(945)	(945)	(945)
Share premium		4,534	4,534	4,534
Share based payment reserve		840	57	794
Retained Earnings		(2,933)	(1,936)	(3,019)
		───────	───────	───────
Total Equity		1,575	1,789	1,443
		───────	───────	───────
LIABILITIES
Current liabilities
Trade and other payables		356	538	318
		───────	───────	───────
		356	538	318
		───────	───────	───────
Non - current liabilities
Deferred tax liability		40	53	47
		───────	───────	───────
		40	53	47
		───────	───────	───────
TOTAL LIABILITIES		396	591	365
		───────	───────	───────
TOTAL EQUITY AND LIABILITIES		1,971	2,380	1,808
		═══════	═══════	═══════

Consolidated Statement of Changes in Equity

For six months to 30 June 2026

	Called up Share Capital	Share premium	Group Reorganisation reserve	Share-based Payment reserve	Retained Earnings	Total Equity
	£'000	£'000	£'000	£'000	£'000	£'000
	──────	───────	───────	───────	──────	───────
Balance at 31 December 2024	79	4,534	(945)	41	(1,786)	1,923
Loss for the period	-	-	-	-	(150)	(150)
Share based payments	-	-	-	16	-	16
	──────	───────	───────	───────	──────	───────
Balance at 30 June 2025	79	4,534	(945)	57	(1,936)	1,789
Loss for the period	-	-	-	-	(1,083)	(1,083)
Share based payments	-	-	-	737	-	737
	──────	───────	───────	───────	──────	───────
Balance at 31  December 2025	79	4,534	(945)	794	(3,019)	1,443
Profit for the period	-	-	-	-	86	86
Share based payments	-	-	-	46	-	46
	──────	───────	───────	───────	──────	───────
Balance at 30 June 2026	79	4,534	(945)	840	(2,933)	1,575
	──────	───────	───────	───────	──────	───────

Consolidated Statement of Cash Flows

For the six months to 30 June 2026

	Notes	6 months to 30 June 2026 Unaudited	Period to 30 June 2025 Unaudited	Year ended 31 December 2025 Audited
		£'000	£'000	£'000
Reconciliation of loss before income tax to cash outflow from operations
Operating profit/(loss)		79	(153)	(1,235)
Decrease/ (Increase) in inventories		-	14	31
(Increase)/decrease in trade and other receivables		(208)	(589)	(94)
(Decrease)/increase in trade and other payables		38	343	123
Share based payments		46	16	753
Depreciation and amortisation		26	25	54
Net Fx Difference			(3)	-
		──────	──────	──────
Net cash outflow from operations		(19)	(347)	(368)
Tax received		-	-	-
		──────	──────	──────
Net cash (outflow)/inflow from operating activities		(19)	(347)	(368)
Cash flows from investing activities
Purchase of intangible assets		(3)	-	(12)
		──────	──────	──────
Net cash (outflow)/inflow from investing activities		(3)	-	(12)
		──────	──────	──────
Cash flows from financing activities
Share issue net of costs		-	-	-
		──────	──────	──────
Net cash inflow from financing activities		-	-	-
		──────	──────	──────
Increase/(decrease) in cash and equivalents		(22)	(347)	(380)
Cash and cash equivalents at beginning of period		1,266	1,646	1,646
		──────	──────	──────
Cash and cash equivalents at end of period		1,244	1,299	1,266
		══════	══════	══════

Notes to the results

For the six months to 30 June 2026

1.    General Information

ProBiotix Health plc is a company incorporated and domiciled in England and Wales. The Company's offices are in Wakefield. The Company is listed on the Aquis Growth Market (ticker: PBX).

The financial information set out in this report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006.  The Group's statutory financial statements for the period ended 31 December 2025 were prepared under UK - adopted International Financial Reporting Standards ("IFRS").

Copies of the annual statutory accounts and the Half Yearly report can be found on the Company's website https://probiotixhealth-ir.com/financials/latest-results

2.    Basis of preparation and significant accounting policies

This report has been prepared using the historical cost convention, on a going concern basis and in accordance with UK - adopted International Financial Reporting Standards ("IFRS").

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the accounting policies and making any estimates. Changes in assumptions may have a significant impact on the financial statements in the period the assumptions changed. The Board of Directors believe that the underlying assumptions are appropriate and that the financial statements are fairly presented. The Board of Directors believes that there are no areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, and therefore, these financial statements have limited disclosures.

3.    Segmental Reporting

In the opinion of the directors, the Group has one class of business, in four geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. The Group sells into three highly interconnected markets, all costs assets and liabilities are derived from locations in the UK and Denmark.

Revenue analysed by geographical market

	6 months 30 June   2026	6 months 30 June   2025	Year to 31 December 2025
	£'000	£'000	£'000
UK	-	34	61
US	1,048	760	1,810
China	276	51	-
ROW	735	499	861
	──────	──────	──────
	2,059	1,344	2,732
	══════	══════	══════

During the reporting period one customer represented £1.014m, 49.2% (2025: £689k, 51.2%) of Group revenues.

4.    Earnings per Share

        Basic earnings per share is calculated by dividing the earnings attributable shareholders by the weighted average number of ordinary shares outstanding during the period.

        Reconciliations are set out below:

	6 Months to 30 June 2026 Unaudited	6 Months to 30 June 2025 Unaudited	Year to 31 December 2025 Audited
	£	£	£
Basic  & Diluted
Earnings attributable to ordinary shareholders	86,000	(150,000)	(1,233,000)
Weighted average number of shares	158,166,666	158,166,666	158,166,666
Earnings /(Loss) per-share - pence	0.05p	(0.09)p	(0.78)p
	═════	═════	═════

        As at 30 June 2026 there were 14,750,000 (2025: 14,750,000) outstanding share options.  These are non-dilutive due to the strike price being above the share price at the period end.

5.   Share Capital

        Issued share capital comprises:

Shares in issue
Opening balance 1 January 2025 and 30 June 2025	158,166,666
	──────
Closing balance at 31 December 2025 and 30 June 2026	158,166,666
	══════

Share capital	£'000
Opening balance 1 January 2025 and 30 June 2025	79
	──────
Closing balance at 31 December 2025 and 30 June 2026	79
	══════

6.   Post balance sheet events

There are no post balance sheet events.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.